A small study found that liraglutide, a GLP-1 medication used to treat obesity and diabetes, reduced opioid cravings by 30% in a small group of patients with opioid use disorder. Those taking liraglutide with buprenorphine were more likely to report zero cravings compared to the placebo group. These results suggest that liraglutide could be an effective treatment for opioid addiction, although the study had limitations such as a small sample size and a high drop-out rate due to side effects. Researchers are planning larger trials to further investigate the potential use of liraglutide for opioid use disorder.
Source link
Opioid cravings were reduced by anti-obesity drug in small study
